The rise of Sildenafil initially sparked a period of growth for the drug industry, but recent changes present a murky scenario for shareholders. Lower-cost alternatives are eating into earnings, and continued patent challenges add further difficulty to the equation. While certain companies may still gain from related services, the general trend sug